Thermo Fisher Finalizes Acquisition of Clario Holdings
TMO sits 24% above its 52-week low of $385.46.
Summary
Thermo Fisher Scientific has completed its acquisition of Clario Holdings, Inc. This follows the company's 10-K filing on February 26, 2026, which announced a major $8.875 billion acquisition. The completion of this deal removes any remaining uncertainty regarding the transaction and allows Thermo Fisher to fully integrate Clario's operations, expanding its clinical research services. Traders will now focus on the financial impact of the acquisition as it begins to contribute to Thermo Fisher's results and the progress of the integration process.
At the time of this announcement, TMO was trading at $478.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $177.6B. The 52-week trading range was $385.46 to $643.99. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.